LEU

Analyst Note: Centrus Energy (LEU)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

Current Price: $191.39 Conservative Entry: — (Breakout not yet fired) Aggressive Entry: $232.00 (Pre-breakout / Forming entry) Breakout Level: $464.25 (Resistance to clear) Extension: —

Classification: The setup is FORMING.

2. Thesis Layer

Primary Secular Thesis: Critical Minerals & Materials → Uranium & Nuclear Fuel (Tier Direct). Exposure Analysis: LEU is a direct beneficiary of the "Critical Minerals" thesis, specifically within the Uranium & Nuclear Fuel sub-sector. The company is positioned as the sole U.S.-licensed provider of High-Assay Low-Enriched Uranium (HALEU) and a primary supplier of Low-Enriched Uranium (LEU). Contextual Tailwinds: The setup is reinforced by the "AI Energy Renaissance" narrative. As of mid-2026, the convergence of AI data center power demands and U.S. government mandates to quadruple nuclear capacity creates a structural supply deficit for domestic enrichment. LEU is not merely a thematic play but a critical infrastructure bottleneck solution. The company's role is "Tier Direct," meaning its revenue is inextricably linked to the physical production and sale of the fuel required for the reactors described in the thesis.

3. The Business

Business Model & Industry: Centrus Energy operates in the Materials sector, specializing in uranium enrichment. Its business model relies on selling enriched uranium (LEU) to domestic and international utilities for commercial nuclear power plants, while simultaneously developing HALEU production capabilities for next-generation reactors and national security applications.

Supporting Evidence (As of 2026-06-13):

• Backlog Strength: As of the Q1 2026 earnings call (May 6, 2026), the company reported a backlog of $3.9 billion, extending through 2040. This includes a substantial commercial LEU enrichment backlog of more than $2.4 billion and 12 metric tons of HALEU.
• Government Contracts: In January 2026, the DOE awarded Centrus subsidiary ACO a $900 million task order to expand its Piketon, Ohio facility for commercial-scale HALEU production. This award is part of a broader initiative where Centrus has contractually produced over 1.6 metric tons of HALEU UF6 for the government since the start of the HALEU operations contract.
• Revenue Guidance: Management raised 2026 annual revenue guidance to a range of $450 million to $500 million (up from $425–$475 million), citing the execution of these backlog items.
• Operational Efficiency: Management identified approximately $300 million in potential cost savings and improvements expected to reduce manufacturing lead times, a finding accelerated through a partnership with Palantir Technologies announced in March 2026.
• Capex & Expansion: The company plans to invest more than $560 million over several years to transition its Oak Ridge centrifuge manufacturing plant to high-rate manufacturing, supporting the production of thousands of advanced centrifuges.

4. Archetype and Conviction

Archetype: Growth Leader. Rationale: The company fits the "Growth Leader" archetype due to its transition from a legacy enrichment provider to a critical enabler of the HALEU market. The combination of a multi-billion dollar backlog, government-backed task orders, and a clear path to commercial-scale HALEU production drives the growth narrative. The "Growth Leader" classification is supported by the management's aggressive guidance raise and the structural necessity of their technology in the national security and commercial nuclear sectors.

Conviction Stack:

• Thesis Strength: High. The "Critical Minerals" thesis is reinforced by geopolitical constraints (Russian Decree, Import Ban Act) and the AI energy demand surge.
• Evidence Quality: Strong. The evidence base includes specific, quantified backlog figures ($3.9B), specific contract awards ($900M), and management guidance updates.
• Setup Readiness: Partial. The coil is in place, but the breakout to $464.25 has not occurred. The current price ($191.39) is significantly below the breakout level, suggesting a potential for a significant run-up if the breakout fires, but also a risk of consolidation.
• Rerating Potential: High. The market is currently pricing in the "Growth Leader" narrative, but the full realization of the $3.9B backlog and the HALEU commercialization could drive a re-rating if the breakout confirms the structural shift.

5. Invalidations, Strengths, and Gaps

Strengthening Factors:

• Confirmation of the $900M HALEU award execution.
• Further guidance raises based on the $300M cost savings realization.
• New commercial HALEU contracts beyond the government awards.
• Successful transition of the Oak Ridge facility to high-rate manufacturing.

Evidence Gaps:

• Specific Data Center Power Forecasts: While the AI narrative is strong, specific data center power consumption forecasts and hyperscaler electricity demand growth rates are missing from the provided evidence.
• Utility Infrastructure Capacity: There is no data on grid interconnection queue data or transformer delivery timelines, which are critical for the physical deployment of the reactors Centrus fuels.
• Private Sector Capex: Direct private sector capex commitments from hyperscalers (beyond the general narrative) are not explicitly detailed in the filings.
• Valuation Context: Forward P/E comparisons to nuclear sector peers are not available in the current evidence set.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: $3.9 billion backlog extending to 2040; $900 million DOE HALEU task order award; Raised 2026 revenue guidance to $450-500 million; Sole U.S. NRC-licensed HALEU producer. Key risks: Technical breakout failure at $464.25; Execution risk on $560 million Oak Ridge capex; High volatility (7.7% ATR) leading to stop-out; Missing data on grid interconnection and hyperscaler power contracts. Expected path: Management expects to leverage the $3.9B backlog and $900M HALEU award to drive revenue growth, with cost savings from the Palantir partnership accelerating lead times. Expected horizon: 6 to 18 months for the backlog to convert to revenue and for the HALEU facility expansion to mature. Failure mode to watch: A sustained close below $189.50, which would invalidate the forming coil structure and suggest a loss of market confidence in the near-term execution.